Truist cuts Community Healthcare Trust stock price target on higher rates

Truist cut its price target on Community Healthcare Trust to $17 from $18, maintaining a Buy rating and citing higher interest rates; shares were quoted at $13.58 after falling 15% over six months. For Q2 2026, revenue was $31.2 million, 1.67% below expectations, and EPS missed the $0.12 estimate by 50%; adjusted FFO was $0.56 per share. The company cut its quarterly dividend 31.3% to $0.33 per share, despite a reported 9.65% yield and 11 consecutive years of dividend increases.

Analysis

The key issue is not the lower price target; it is whether CHCT can fund its way through a higher-rate environment without sacrificing portfolio growth or balance-sheet flexibility. Higher financing costs can pressure both property-level returns and acquisition economics, making occupancy upside less valuable if incremental capital is expensive. A dividend reduction, if confirmed, also removes a key support for income-oriented demand and may raise the equity’s cost of capital just as the company needs funding options.

There is a material inconsistency in the report: it cites a 9.65% yield and an 11-year dividend-raise streak, but also says the latest results included a 31.3% dividend cut. Those claims cannot be treated as contemporaneous without verifying the dates, periods, and dividend amount. Resolve this against CHCT’s filings before using the yield or dividend history in valuation.

Near term, the stock’s proximity to its low and a Buy rating may offer little support if investors are already pricing in rate pressure. Over 1–3 months, watch financing costs, occupancy, AFFO coverage, and any guidance on the Assurance transition or capital recycling. Over 6–18 months, sustained high rates could constrain acquisitions and make external equity issuance more dilutive. The contrarian case is that the valuation discount may already reflect understood rate drag—but that is not enough to establish a floor if cash distributions or AFFO weaken further.

Key Decisions for Investors

• Do not buy CHCT solely on the stated target upside or headline yield. First reconcile the dividend claims with the latest company filing and verify AFFO per share, payout coverage, debt maturities, and variable-rate exposure.
• Maintain a cautious/underweight bias until coverage and funding data are clear. Reassess if occupancy improves while AFFO remains stable and management demonstrates a credible, non-dilutive funding path.
• For a relative-value expression, consider underweighting CHCT against a diversified healthcare REIT basket rather than taking an outright short; size only after checking borrow cost, liquidity, and peer balance-sheet differences.
• Falsifiers: a sustained improvement in AFFO and occupancy, lower financing costs, or evidence that the reported dividend cut is stale or misattributed would weaken the cautious thesis. Further distribution reductions, weaker coverage, or dilutive capital raising would strengthen it.